Ann: Breakthrough Zantrene Heart Protection Discovery, page-341

Great research, mate.

The MYC transcript probably won't play a part in the cardioprotection seen in our results, because other FTO inhibitors did not confer protection in the same way Zantrene did. Unlike cancerous cells, cardiomyocytes will behave in a predictable manner, where inhibition of FTO has the same outcome between peoples; cancerous cells can have unique characterstics and behaviours whereas non-cancerous cells are more conformative to the tissue of origin (those that act outside a set of parameters are usually destroyed by the body). Therefore, if MYC was the target transcript influencing cardioprotection and inhibiting FTO led to altered activity of MYC, then it should not matter how FTO was inhibited (pharmacological or gene knockout) to see a positive result. This is not demonstrated in the data, as Zantrene provides cardioprotection while others either don't or increase cardiac damage. All compounds are inhibiting FTO, so this tells me that there is another undiscovered mechanism that is driving this protection.